Wide Ranks

GLUE

Monte Rosa Therapeutics, Inc.

9.11

Top Statistics
Market Cap 559 M Forward PE -5.86 Revenue Growth 0.00 %
Current Ratio 6.03 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.98 Enterprise / Revenue 24.12 Price To Sales Trailing12 Months 37.37
Profitability
Profit Margins 0.00 % Operating Margins -287.84 %
Balance Sheet
Total Cash 242 M Total Cash Per Share 3.94 Total Debt 43 M
Total Debt To Equity 21.27 Current Ratio 6.03 Book Value Per Share 3.35
All Measures
Short Ratio 223.00 % Message Board Id finmb_690261281 Shares Short Prior Month 5 M
Return On Equity -0.6123 City Boston Uuid e1526429-092c-3bce-8f14-de475e92b666
Previous Close 8.60 First Trade Date Epoch Utc 1 B Book Value 3.35
Beta 1.30 Total Debt 43 M Volume 630197
Price To Book 2.72 Fifty Two Week Low 2.92 Total Cash Per Share 3.94
Total Revenue 14 M Shares Short Previous Month Date 1 B Target Median Price 15.00
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -287.84 %
Target Mean Price 16.43 Net Income To Common -119389000 Short Percent Of Float 0.3316
Implied Shares Outstanding 61 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 847020 Average Volume10days 847020 Total Cash 242 M
Next Fiscal Year End 1 B Revenue Per Share 0.2210 Held Percent Insiders 0.0070
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 8.60 Target Low Price 14.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 6.93 Open 8.73 Free Cashflow -47188876
State MA Dividend Yield 0.00 % Return On Assets -0.2843
Time Zone Short Name EST Trailing Eps -1.78 Day Low 8.62
Address1 321 Harrison Avenue Shares Outstanding 61 M Price Hint 2
Target High Price 20.00 Website https://www.monterosatx.com 52 Week Change 1.94
Average Volume 2 M Forward Eps -1.50 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 583.00 % Is_sp_500 False
Regular Market Day High 9.25 Profit Margins 0.00 % Debt To Equity 21.27
Fifty Two Week High 12.40 Day High 9.25 Shares Short 11 M
Regular Market Open 8.73 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 24.12 Revenue Growth 0.00 % Shares Percent Shares Out 0.1815
Operating Cashflow -57292000 Currency USD Time Zone Full Name America/New_York
Market Cap 559 M Is_nasdaq_100 False Zip 02118
Quote Type EQUITY Industry Biotechnology Long Name Monte Rosa Therapeutics, Inc.
Regular Market Day Low 8.62 Held Percent Institutions 0.9063 Current Price 9.11
Address2 Suite 900 Enterprise To Ebitda -2.98 Financial Currency USD
Current Ratio 6.03 Gross Margins 112.03 % Industry Disp Biotechnology
Number Of Analyst Opinions 7 Country United States Float Shares 38 M
Two Hundred Day Average 5.71 Enterprise Value 361 M Price To Sales Trailing12 Months 37.37
Forward PE -5.86 Regular Market Volume 630197 Ebitda -121073000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.

The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.

It also develops CDK2 to treat ovarian, uterine, and breast cancers.

The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.